TY  - JOUR
T1  - ACute stroke therapy at the crossroads
AU  - Broderick JP, Meyers PM
Y1  - 2011/11/09
N1  - 10.1001/jama.2011.1622
JO  - JAMA
SP  - 2026
EP  - 2028
VL  - 306
IS  - 18
N2  - 
Intravenous tissue plasminogen activator (IV t-PA) is the only treatment approved by the Food and Drug Administration (FDA) that was proven clinically effective in multiple randomized clinical trials for acute ischemic stroke.1 The effectiveness of t-PA is time-dependent; treatment beyond 4.5 hours from stroke onset does not result in improved clinical outcome.1 By reducing long-term disability, IV t-PA is also highly cost-effective.2 No other treatment for acute ischemic stroke has shown greater clinical efficacy than IV t-PA.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2011.1622
UR  - http://dx.doi.org/10.1001/jama.2011.1622
ER  -